AMVUTTRA

This brand name is authorized in United States. It is also authorized in Croatia, Japan, Lithuania, Romania, UK.

Active ingredients

The drug AMVUTTRA contains one active pharmaceutical ingredient (API):

1	Vutrisiran UNII 28O0WP6Z1P - VUTRISIRAN SODIUM
	Vutrisiran is covalently linked to a ligand containing three N-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes. Through a natural process called RNA interference (RNAi), vutrisiran causes the catalytic degradation of TTR mRNA in the liver, resulting in the reduction of variant and wild-type serum TTR protein levels.
	Read more about Vutrisiran

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AMVUTTRA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07XX18		N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
JP	医薬品医療機器総合機構	1290401G1021
LT	Valstybinė vaistų kontrolės tarnyba	1095553
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69347001
US	FDA, National Drug Code	71336-1003